case_images: PMC8830913_01
case_images: Schedule of treatment and dynamics of platelet counts for patient 1. After two courses of tislelizumab treatment, the platelet count gradually decreased with the lowest level of 0.5x104/microL, which was refractory to glucocorticoids, IVIG, rh-TPO, cyclosporine and eltrombopag. With the administration of avatrombopag 40 mg daily, the platelet count rapidly increased and remained above 10x104/microL.
case_images: fphar-12-795884-g001.jpg
case_images: PMC8830913_01_fphar-12-795884-g001.jpg
case_images: F1
case_images: To date, the platelet count of the patient has remained normal (Figure 1), and no obvious adverse effects have been observed.
case_images: PMC8830913_02
case_images: Schedule of treatment and the dynamics of white blood cells, hemoglobin and platelets for patient 2. Two courses of triplezumab treatment induced a gradually decreased platelet count followed by pancytopenia with no response to glucocorticoids, IVIG, rh-TPO or eltrombopag. With the use of avatrombopag 40 mg daily, a rapid increase in platelet count, hemoglobin and white blood cell count was observed and maintained.
case_images: fphar-12-795884-g002.jpg
case_images: PMC8830913_02_fphar-12-795884-g002.jpg
case_images: F2
case_images: Two months after the avatrombopag administration, a satisfactory blood cell count was achieved with a platelet count of 9.4x104/microL, a hemoglobin count of 10.6 g/dl and a white blood cell count of 3.2x103/microL (Figure 2).